Glaukos has filed a patent for drug delivery ocular implants. The implants consist of an elongate outer shell with a lumen containing therapeutic agents. The outer shell has regions for drug release and is designed for implantation in the anterior chamber of the eye. GlobalData’s report on Glaukos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glaukos, customized implants was a key innovation area identified from patents. Glaukos's grant share as of September 2023 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Ocular implants for drug delivery in the eye
A recently filed patent (Publication Number: US20230301830A1) describes a drug delivery ocular implant designed to treat ocular conditions or disorders. The implant consists of an elongate outer shell with a proximal and distal end, enclosing an interior space that contains one or more therapeutic agents. The implant also includes one or more regions of drug release. The unique feature of this implant is its ability to be deformed from a straightened to an arcuate shape, allowing it to be retained within the eye.
The patent also mentions the inclusion of a retention protrusion in the implant, which aids in its retention within the eye. Additionally, the implant can be either biodegradable or non-biodegradable, depending on the desired application. The therapeutic agents used in the implant include prostaglandins, prostaglandin analogs, alpha-blockers, or beta-blockers, with specific examples such as latanoprost, travoprost, timolol, and brimonidine.
The drug release from the implant is modulated by the one or more regions of drug release, which can control the release rate of the therapeutic agents. The elongate outer shell of the implant can be semi-permeable or substantially impermeable to the therapeutic agents, with the latter having one or more orifices for elution of the agents. These orifices may also include a material that is semi-permeable to the therapeutic agents.
The patent also describes a method for delivering the drug delivery ocular implant. This involves advancing a needle containing the implant through the corneal tissue of the eye, positioning the needle within the eye, activating the actuator to expel the implant, and withdrawing the needle. This results in the implant becoming substantially immobilized within the eye.
Furthermore, the patent outlines a method of treating ocular conditions or disorders using the drug delivery implant. This involves creating a self-sealing opening in the cornea to access the eye, inserting the implant into the predetermined portion of the eye, and withdrawing the delivery device. The drug elutes from the implant to treat the ocular condition or disorder, with the therapeutic effect lasting for at least one year.
Overall, this patent presents a novel drug delivery ocular implant and methods for its delivery and treatment of ocular conditions or disorders. The implant's unique design and drug release capabilities make it a promising solution for ocular drug delivery.
To know more about GlobalData’s detailed insights on Glaukos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
